profit from every $100 of sales.
$0$100
RTW Biotech Opportunities
$2.44-1.61% today
+38.2% in 1 year
1-year low $1.761-year high $2.61
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
You pay $3.18 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What RTW Biotech Opportunities sold, what it kept, and what it did with the cash.
Sales went from -$36.5 million in 2022 to $251 million in 2025, with $245 million of profit last year.
SalesProfit
RTW Biotech Opportunities handed back 12% of the cash it generated last year.
Buybacks $13M
Free cash flow 2025$105M
Bought back its own shares$13M
Paid as dividends–
RTW Biotech Opportunities vs. similar companies
RTW Biotech Opportunities grows the fastest of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| RTW Biotech Opportunities | 3.2× · Cheap | ||
 BlackRock | 34.0× · Expensive | ||
 Blackstone | 49.1× · Expensive | ||
 Investor | 8.5× · Cheap | ||
 Brookfield | 70.0× · Very expensive |
AI analysis
An AI analyst reads RTW Biotech Opportunities's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -37 | 86 | 39 | 251 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| -39 | 83 | 34 | 245 | |
| -0.17 | 0.36 | 0.11 | 0.63 | |
| – | – | – | – | |
| – | – | – | – | |
| 108.0% | 96.4% | 88.3% | 97.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 402 | 446 | 760 | 1,069 |
| Cash | 7 | 3 | 5 | 6 |
| Total debt | – | – | – | – |
| Total liabilities | 54 | 17 | 127 | 204 |
| 348 | 429 | 633 | 865 | |
| 232 | 231 | 311 | 389 | |
| – | – | – | – | |
| -11.3% | 19.4% | 5.4% | 28.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 10 | 34 | -124 | 105 | |
| – | – | – | – | |
| 10 | 34 | -124 | 105 | |
| Dividends paid | 0 | – | – | – |
| 0 | 2 | 11 | 13 | |
| – | – | – | – |
Valuation
- 3.2×
- –
- 0.10
- 0.8×
- 3.1×
- 7.4×
- –
- 13.5%
- 31.5%
- –
Profitability
- –
- –
- 97.7%
- –
- –
- –
- –
- –
- –
- –
Growth
- +70.5%
- +32.3%
- –
- –
- +18.8%
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Financial Services
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 2%of 883
Top 5%of 880
Top 16%of 929
News
The Top 5 Biotech Stocks I'd Buy Right Now Without Any HesitationYahoo Finance · Nov 8, 2026Cathie Wood-Led Ark Loads Up On GOOG, AMD, NVDA And Biotech Stocks — But Sells CRWV, AVGO, LLYYahoo Finance · Nov 7, 2026Stock Market Today: Dow Dips On Election Day; These Biotech, Insurance Stocks Clear Entries (Live Coverage)Yahoo Finance · Nov 3, 20261 Dividend-Paying Biotech Stock to Buy Hand Over Fist in NovemberYahoo Finance · Nov 1, 20265 Best Biotech Stocks Under $10 to BuyYahoo Finance · Oct 31, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about RTW Biotech Opportunities
Is RTW Biotech Opportunities a good stock to buy?
A strong, very profitable business, and the price looks low. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the RTW Biotech Opportunities AI analysis
What does RTW Biotech Opportunities do?
RTW Biotech Opportunities Ltd is a venture capital fund. The fund specializes in directly investing and early-stage. The fund specializes in identifying transformative assets with high growth potential across the life sciences, biopharmaceutical and medical technology sectors. It is in Asset Management, based in New York, NY, United States.
Does RTW Biotech Opportunities pay a dividend?
No. RTW Biotech Opportunities does not pay a dividend at the moment; in 2025 it returned $12.6 million to shareholders by buying back its own shares.
How has RTW Biotech Opportunities stock done over the past year?
Up 38.2% over the past twelve months, to $2.44. It traded between $1.76 and $2.61 and is 6.5% below its high.
Who are RTW Biotech Opportunities's competitors?
The largest listed companies in the same industry are BlackRock, Blackstone, Investor and Brookfield. The peers table on this page compares their profit, growth and price with RTW Biotech Opportunities's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.